A Post-market Feasibility Study Evaluating Location Accuracy Using the superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology in Subjects Undergoing Lung Lesion Biopsy
Phase: NA
Conditions: Lung Cancer
Sponsor: Medtronic - MITG

161 Cheshire Lane  
Suite 100 
Plymouth, MN 55441  
USA 
www.medtronic.com 
Official Title:  A Post-market Feasibility Study Evaluating Location Accuracy Using the superDimension™ 
Navigation System Version 7.2 With Fluoroscopic Navigation Technology in Subjects Undergoing Lung Lesion 
Biopsy 
 
ClinicalTrials.gov ID: NCT03585959 
 
Date of Document: 09Apr2018 
 
 

Fluoroscopic Navigation Clinical Investigation Plan 
MDT18004ILSFNV 
Version 1.0 
Page 1 of 54 
This document is electronically controlled 
056-F275, v3.0 Clinical Investigation Plan Template
Clinical Investigation Plan 
Clinical Investigation Plan/Study Title A post-market feasibility study evaluating 
location accuracy using the superDimension™ 
Navigation System Version 7.2 with Fluoroscopic 
Navigation Technology in subjects undergoing 
lung lesion biopsy 
Clinical Investigation Plan Identifier MDT18004ILSFNV 
Study Product Name superDimension™ Navigation System Version 7.2 
with Fluoroscopic Navigation Technology 
Sponsor/Local Sponsor Medtronic  
Lung Health 
Minimally Invasive Therapies Group 
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
Document Version Final Version 1.0, 09-APR-2018 
Co-Principal Investigators Michael A. Pritchett DO MPH 
Pulmonary Disease & Critical Care Medicine 
FirstHealth Moore Regional Hospital 
Pinehurst Medical Clinic 
Krishnendu Bhadra MD 
Interventional Pulmonology 
CHI Memorial Medical Group 
 
 
 
 
Covidien llc is an indirect wholly owned subsidiary of Medtronic plc. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 2 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
1. Investigator Statement 
Study product Name 
superDimension™ Navigation System Version 7.2 with 
Fluoroscopic Navigation Technology 
Sponsor 
Medtronic  
Lung Health 
Minimally Invasive Therapies Group  
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
Clinical Investigation Plan Identifier 
 MDT18004ILSFNV 
Version Number/Date  
Final Version 1.0, 09-APR-2018 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for 
me and my staff to conduct this study as described. I will conduct this study as outlined herein and 
will make a reasonable effort to complete the study within the time designated. 
I agree to comply with ISO 14155:2011 (Clinical Investigation of Medical Devices for Human Subjects – 
Good Clinical Practice) and the International Conference on Harmonisation (ICH) of Technical 
Requirements For Registration of Pharmaceuticals For Human Use, ICH Harmonised Tripartite 
Guideline for Good Clinical Practice E6 (R1). I agree to ensure that the confidential information 
contained in this document will not be used for any purpose other than the evaluation and conduct of 
the clinical investigation without the prior written consent of Medtronic. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Medtronic. I will discuss this material with them to ensure that they are fully 
informed about the products and the study. 
Principal Investigator’s Signature: 
 
Principal Investigator’s Name: 
 
Institution: 
 
Date: 
 
 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 3 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Table of Contents  
1. 
Investigator Statement ...................................................................................................... 2 
2. 
Glossary .............................................................................................................................. 6 
2.1. Terms .................................................................................................................................. 6 
2.2. Definitions ............................................................................................................................ 7 
3. 
Synopsis ........................................................................................................................... 10 
4. 
Introduction ..................................................................................................................... 15 
4.1. Background ........................................................................................................................ 15 
4.2. Purpose .............................................................................................................................. 16 
5. 
Objectives and Endpoints ................................................................................................. 16 
5.1. Primary Objective ................................................................................................................ 16 
5.2. Primary Endpoint ................................................................................................................ 16 
5.3. Secondary Endpoints ........................................................................................................... 18 
5.4. Safety Endpoints ................................................................................................................. 18 
6. 
Study Design .................................................................................................................... 19 
6.1. Duration ............................................................................................................................. 19 
6.2. Rationale ............................................................................................................................ 19 
7. 
Product Description.......................................................................................................... 20 
7.1. General .............................................................................................................................. 20 
7.2. Dosage Form and Route of Administration ............................................................................. 22 
7.3. Manufacturer ...................................................................................................................... 22 
7.4. Packaging ........................................................................................................................... 22 
7.5. Intended Population ............................................................................................................ 22 
7.6. Equipment .......................................................................................................................... 22 
7.7. Product Use ........................................................................................................................ 23 
7.8. Product Training Requirements ............................................................................................. 25 
7.9. Product Receipt and Tracking ............................................................................................... 26 
7.10. 
Product Storage ............................................................................................................. 26 
7.11. 
Product Return .............................................................................................................. 26 
7.12. 
Product Accountability .................................................................................................... 26 
7.13. 
Intended Claims ............................................................................................................ 26 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 4 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
8. 
Selection of Subjects ........................................................................................................ 26 
8.1. Study Population ................................................................................................................. 26 
8.2. Subject Enrollment .............................................................................................................. 27 
8.2.1. 
Roll-in Subjects ...................................................................................................................... 27 
8.3. Inclusion Criteria ................................................................................................................. 27 
8.4. Exclusion Criteria................................................................................................................. 27 
9. 
Study Procedures ............................................................................................................. 28 
9.1. Schedule of Events .............................................................................................................. 28 
9.1.1. 
Overview of Study Procedures .............................................................................................. 29 
9.2. Subject Screening ............................................................................................................... 30 
9.3. Prior and Concomitant Medications ....................................................................................... 30 
9.4. Subject Consent .................................................................................................................. 30 
9.5. Randomization and Treatment Assignment ............................................................................ 30 
9.6. Medication Compliance ........................................................................................................ 31 
9.7. Assessment of Efficacy ........................................................................................................ 31 
9.7.1. 
Baseline ................................................................................................................................. 31 
9.7.2. 
Procedure Day ....................................................................................................................... 31 
9.7.3. 
Procedure Details .................................................................................................................. 31 
9.7.4. 
Study Completion .................................................................................................................. 32 
9.8. Assessment of Safety .......................................................................................................... 32 
9.9. Recording Data ................................................................................................................... 32 
9.10. 
Deviation Handling ........................................................................................................ 33 
9.11. 
Subject Withdrawal or Discontinuation ............................................................................. 33 
10. Risks and Benefits ............................................................................................................ 34 
10.1. 
Potential Risks ............................................................................................................... 34 
10.1.1. 
Summary MDR Reportable Event Trend & Risk Analysis Report....................................... 34 
10.1.2. 
Study-related Imaging ....................................................................................................... 37 
10.2. 
Potential Benefits ........................................................................................................... 38 
10.3. 
Risk-Benefit Rationale .................................................................................................... 38 
11. Adverse Events and Device Deficiencies .......................................................................... 38 
11.1. 
Definitions/Classifications ............................................................................................... 38 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 5 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
11.1.1. 
Adverse Event (AE) ............................................................................................................ 39 
11.1.2. 
Serious Adverse Event (SAE) .............................................................................................. 39 
11.1.3. 
Adverse Device Effect (ADE) .............................................................................................. 39 
11.1.4. 
Serious Adverse Device Effect (SADE) ............................................................................... 40 
11.1.5. 
Unanticipated Serious Adverse Device Effect (USADE) ..................................................... 40 
11.1.6. 
Device Deficiency ............................................................................................................... 40 
11.1.7. 
Adverse Event Relationship Classification ......................................................................... 40 
11.1.8. 
Adverse Event Outcome Classification .............................................................................. 42 
11.2. 
Reporting of Adverse Events ........................................................................................... 42 
11.2.1. 
Notification to Authorities ................................................................................................. 43 
12. Data Review Committees ................................................................................................. 44 
13. Statistical Design and Methods ........................................................................................ 44 
14. Ethics ................................................................................................................................ 45 
14.1. 
Statement(s) of Compliance ........................................................................................... 45 
15. Study Administration ....................................................................................................... 46 
15.1. 
Monitoring .................................................................................................................... 46 
15.2. 
Data Management ......................................................................................................... 47 
15.3. 
Direct Access to Source Data/Documents ......................................................................... 47 
15.4. 
Confidentiality ............................................................................................................... 47 
15.5. 
Liability ......................................................................................................................... 48 
15.6. 
CIP Amendments ........................................................................................................... 48 
15.7. 
Record Retention ........................................................................................................... 48 
15.8. 
Publication and Use of Information .................................................................................. 48 
15.9. 
Suspension or Early Termination ..................................................................................... 49 
15.10. 
Study Contact Information .............................................................................................. 50 
16. References ....................................................................................................................... 50 
17. Appendices ....................................................................................................................... 53 
17.1. 
Sample Patient Informed Consent ................................................................................... 53 
17.2. 
User Manual .................................................................................................................. 53 
18. Version History ................................................................................................................. 54 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 6 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
2. Glossary 
2.1. Terms 
Acronym / Term 
Definition 
AE 
adverse event 
AP 
anteroposterior 
CBCT 
cone-beam computed tomography 
CIP 
clinical investigation plan 
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events  
EC 
Ethics Committee 
ENB 
electromagnetic navigation bronchoscopy 
eCRF 
electronic case report form 
EWC 
extended working channel 
FDA 
Food and Drug Administration 
GCP 
good clinical practice 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFU 
instructions for use 
ILS 
Medtronic Interventional Lung Solutions 
IRB 
institutional review board 
LG 
locatable guide 
MDR 
medical device reporting  
ROSE 
rapid on-site evaluation 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 7 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
2.2. Definitions 
Adequate Periprocedural Location 
The location of the extended working channel when the proceduralist makes the decision that 
placement is adequate and clinically acceptable to proceed with tissue sampling based on location 
confirmation by cone-beam computed tomography (CBCT). 
Adverse Event 
Please refer to Section 11.1.1. 
Bronchopulmonary Hemorrhage 
A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma. Degree of 
severity will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) grade 
as follows (a semicolon indicates “or” within the description of the grade): 
• 
Grade 1: Mild symptoms; intervention not indicated 
• 
Grade 2: Moderate symptoms; medical intervention indicated 
• 
Grade 3: Transfusion, invasive intervention indicated (e.g., hemostasis of bleeding site) 
• 
Grade 4: Life-threatening respiratory or hemodynamic compromise; intubation or urgent 
intervention indicated 
• 
Grade 5: Death 
Common Terminology Criteria for Adverse Events 
A set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy. 
The CTCAE system is a product of the US National Cancer Institute (NCI) Cancer Therapy Evaluation 
Program (CTEP).1 This protocol will use Version 5.0, available at 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50https://ctep.canc
er.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50  
ENB Procedure Time 
Total time from the first entry of the extended working channel or locatable guide until the last exit of 
the extended working channel. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 8 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Device Deficiency 
See Section 11.1.6. 
Investigational Medical Device 
For the purpose of this clinical investigation plan, an Investigational Medical Device is defined as, “a 
device, including a transitional device, which is the object of an investigation.” The Investigational 
Medical Device being evaluated in this study is the superDimension™ Navigation System Version 7.2 
with Fluoroscopic Navigation Technology, which has been cleared by the FDA. 
Lesion Size 
Defined as greatest diameter of target lesion. 
Navigation Success 
The proportion of cases in which the operator is able to successfully navigate to the lung target with ENB 
guidance and obtain tissue for biopsy. 
Pneumothorax 
A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the 
lung. Degree of severity will be classified according to CTCAE grade as follows (a semicolon indicates “or” 
within the description of the grade): 
• 
Grade 1: Asymptomatic; clinical or diagnostic observations only; intervention not indicated 
• 
Grade 2: Symptomatic; intervention indicated (e.g., tube placement without sclerosis) 
• 
Grade 3: Sclerosis and/or operative intervention indicated; hospitalization indicated 
• 
Grade 4: Life-threatening consequences; urgent intervention indicated 
• 
Grade 5: Death 
Relational Accuracy 
Describes the 3-dimensional relationship between the catheter and the lesion in terms of distance, 
vector, and trajectory. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 9 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Respiratory Failure 
A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a 
decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of 
carbon dioxide. Degree of severity will be classified according to CTCAE grade as follows (a semicolon 
indicates “or” within the description of the grade): 
• 
Grade 4: Life-threatening consequences; urgent intervention, intubation, or ventilatory support 
indicated 
• 
Grade 5: Death 
Serious Adverse Event 
Please refer to Section 11.1.2. 
Technical Success 
Successful completion of Local Registration utilizing Fluoroscopic Navigation Technology in 
superDimension™ Navigation System Version 7.2. 
Total Procedure Time 
Total time from the first entry of the bronchoscope to the last exit of the bronchoscope. 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 10 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
3. Synopsis 
Title 
A post-market feasibility study evaluating location accuracy using the 
superDimension™ Navigation System Version 7.2 with Fluoroscopic 
Navigation Technology in subjects undergoing lung lesion biopsy 
Clinical Study Type 
Post-Market Feasibility 
Product Name 
superDimension™ Navigation System Version 7.2 with Fluoroscopic 
Navigation Technology 
Sponsor  
Medtronic  
Lung Health 
Minimally Invasive Therapies Group  
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
Investigation Purpose 
The purpose of this investigation is to confirm the clinical accuracy of 
the superDimension™ Navigation System Version 7.2 with 
Fluoroscopic Navigation Technology. 
Product Status 
superDimension™ Navigation System Version 7.2 is cleared by FDA 
Primary Objective 
The primary objective of this post-market feasibility study is to 
confirm the location accuracy of the local registration feature of the 
superDimension™ Navigation System Version 7.2 in subjects 
undergoing lung lesion biopsy. 
Primary Endpoint 
The Primary Endpoint is the measured ability of the superDimension™ 
Navigation System v7.2 with Fluoroscopic Navigation Technology to 
place the center of the virtual navigation target (green ball) on the 
intended target lesion as confirmed by cone-beam computed 
tomography (CBCT).  
The primary endpoint will be evaluated in Technically Successful cases 
(local registration complete). 
Secondary Objectives 
The following secondary endpoints will be evaluated in all enrolled 
subjects: 
• 
Number of cases that are technically successful (successful 
completion of local registration) 
• 
In cases that are not technically successful, reason for 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 11 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
incomplete local registration in each target lesion 
• 
Investigator confirmation that the catheter is in an “Adequate 
Periprocedural Location” (the location of the extended 
working channel with the proceduralist makes the decision 
that placement is adequate and clinically acceptable to 
proceed with tissue sampling based on location confirmation 
by CBCT) 
• 
Total procedure time 
• 
ENB procedure time 
• 
Total fluoroscopy time, as measured by the fluoroscopy 
system 
• 
Adequacy of the ENB-aided tissue sample for rapid on-site 
evaluation (ROSE) of cytologic samples by pathology (when 
applicable) 
• 
Histopathological call based on ROSE of the ENB-aided tissue 
sample (when applicable) 
• 
Final pathology results of the ENB-aided tissue sample 
• 
Biopsy tools used, tool order, number of passes, and 
diagnoses for each tool based on ROSE and final pathology of 
the ENB-aided sample 
In Technically Successful cases (local registration complete): 
• 
Percentage of cases in which the intended lesion is correctly 
identified (as opposed to a non-target lesion or normal lung 
tissue) as indicated by the system software. 
• 
Relational Accuracy in cases in which the Intended lesion is 
targeted. 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 12 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Safety Assessments 
The following safety endpoints will be evaluated in all enrolled 
subjects. These events will be evaluated for their relationship to the 
study device and study procedure, and classified according to 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.  
• 
Incidence of all pneumothorax related to ENB index 
procedure 
• 
Incidence of CTCAE Grade ≥2 pneumothorax related to the 
ENB index procedure  
• 
Incidence of all bronchopulmonary hemorrhage related to 
ENB index procedure 
• 
Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage 
related to the ENB index procedure  
• 
Incidence of CTCAE Grade≥4 respiratory failure related to ENB 
index procedure  
In addition to the Safety Endpoints described above, all Adverse 
Events related to the superDimension™ navigation system, associated 
tools, or ENB procedure will be collected. 
Adverse events and safety endpoints will be collected immediately 
post-procedure and at 7 days post procedure. 
Study Design 
This post-market feasibility study will include subjects who meet the 
criteria specified below. Assessments will occur at baseline, during 
and immediately after the procedure, and at 7 days post procedure by 
telephone. 
Randomization 
Not Applicable  
Clinical Sites 
Up to 5 clinical sites in the United States are planned 
Sample Size 
This study will enroll up to 50 subjects meeting the inclusion criteria, 
with a maximum of 25 subjects per site. 
A maximum of five roll-in cases will be allowed per investigator, as 
described in Section 8.2.1. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 13 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Inclusion/Exclusion Criteria 
Inclusion Criteria 
1. Subject presents with lung lesion(s) greater than 10 mm in 
diameter amenable to evaluation by ENB at the time of 
evaluation 
2. Lesion is intended to be biopsied by the participating 
investigator 
3. Subject is willing and able to provide informed consent to 
participate in the study 
4. Subject is a candidate for an elective ENB procedure 
5. Subject is over the age of 18 
Exclusion Criteria 
1. Central lesions that are not visible endobronchially or could 
be reached by a flexible bronchoscope or endobronchial 
ultrasound (EBUS) without the utilization of ENB 
2. Lesions within 10 mm of the diaphragm 
3. The subject is unable or unwilling to comply with study 
follow-up schedule 
4. The subject has participated in an investigational drug or 
device research study within 30 days of enrollment that 
would interfere with this study 
5. Female subjects who are pregnant or nursing as determined 
by standard site practices  
Study Procedures and 
Assessments 
Enrolled subjects will first undergo a standard ENB procedure to 
navigate to within 2.5 cm of the target lesion. Local registration with 
Fluoroscopic Navigation Technology will be conducted and 
fluoroscopy and CBCT scans will be used to document that the biopsy 
tool is correctly positioned in the target lesion in three dimensions. 
Efficacy endpoints will be collected during the procedure and safety 
will be evaluated through 7-day follow-up, as described above. 
Statistics 
No formal statistical comparisons or sample size calculations will be 
made for this post-market feasibility study. 
Interim Analysis:  Will be conducted after roll-in procedures have 
been completed for the purpose of evaluating workflow and data 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 14 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
validity. 
Final Analysis: Will be conducted after all subjects have completed 
the procedure and the 7-day follow-up for the purpose of evaluating 
the primary and secondary endpoints. 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 15 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
4. Introduction  
4.1. Background  
Electromagnetic navigation bronchoscopy (ENB) using the superDimension™ navigation system is an 
image-guided approach that uses three-dimensional reconstructed computed tomography (CT) scans 
and sensor location technology to guide endoscopic tools to lung lesions.2 To date, over thirty clinical 
studies with data from over 2,100 subjects have been published describing outcomes of ENB-aided 
biopsy of peripheral lung lesions using the superDimension™ navigation system. ENB-aided diagnostic 
yield ranges from 39% to 97%.3-34 Pneumothorax is the most common complication, occurring in 
approximately 3% of patients in a recent meta-analysis,35 lower than the pooled 20% rate reported for 
transthoracic needle biopsy.36 The prospective, multicenter NAVIGATE study evaluated ENB using the 
superDimension™ navigation system v7.0 and v6.0. Pneumothorax CTCAE Grade ≥2 occurred in 3.2% of 
subjects. Any-grade pneumothorax occurred in 4.9% of subjects. Bronchopulmonary hemorrhage was 
1.0% CTCAE Grade ≥2 and 2.3% overall. CTCAE Grade ≥4 respiratory failure occurred in 0.6% of subjects. 
There were no deaths related to the ENB device or associated tools.37  
Despite the volume of safety and efficacy data on the superDimension™ navigation system, one 
remaining challenge is that the reconstructed images are based on pre-procedure CT scans of the 
patient without real-time confirmation of catheter location relative to the target lesion. In addition, CT-
to-body divergence can occur when the patient’s anatomy does not perfectly align with the three-
dimensional CT. Because the inhale level during the CT scan is different than during the procedure, the 
volume and shape of the lung are different. Other factors resulting in deformation or divergence from 
the original CT may include the presence and push by the bronchoscope or catheter, the reaction of 
airway muscles to sedation or anesthesia, a different patient position, bed curvature, and anatomical 
changes. 
While real-time fluoroscopy is frequently used during ENB to circumvent these challenges, small lesions 
or those obscured by dense tissue, blood vessels, or bone may not be clearly visible under two-
dimensional fluoroscopy.38 Anatomy can also be blurred together rather than clearly separated. In the 
NAVIGATE study, at least 40% of lung lesions were not visible on fluoroscopy.37 
The superDimension™ navigation system version 7.2 is a modification of the version 7.1 system. Version 
7.2 (v7.2) adds fluoroscopic navigation technology with enhanced three-dimensional fluoroscopy to 
improve the physician’s ability to biopsy lung lesions by rotating the fluoroscope laterally around the 
lesions. The fluoroscopic navigation technology allows for optional local registration that updates the 
catheter position relative to the target using fluoroscopic images with ENB to compensate for CT-to-
body divergence during the procedure. The local registration process focuses on a small region of 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 16 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
interest around the target and refines the three-dimensional model based on the fluoroscopic image 
data. This takes into consideration any changes in the patient’s positioning or other changes compared 
to the CT scan. Because the data is taken at the time of the procedure and covers a specific region of the 
lung, the system can create a more precise model around the target thus minimizing local CT-to-body 
divergence.  
The current feasibility study will evaluate the location accuracy of the superDimension™ Navigation 
System v7.2 with Fluoroscopic Navigation Technology to determine if the local registration feature 
allows accurate lesion targeting, with the same safety profile observed for previous superDimension 
navigation system versions.  
4.2. Purpose 
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation 
System v7.2 with Fluoroscopic Navigation Technology. 
5. Objectives and Endpoints 
5.1. Primary Objective 
The primary objective of this post-market feasibility study is to confirm the location accuracy of the local 
registration feature of the superDimension™ navigation system v7.2 in subjects undergoing lung lesion 
biopsy. 
5.2. Primary Endpoint 
The Primary Endpoint is the measured ability of the superDimension™ Navigation System v7.2 with 
Fluoroscopic Navigation Technology to place the center of the virtual navigation target (green ball) on 
the intended target lesion as confirmed by CBCT.  
The primary endpoint will be evaluated in Technically Successful cases (local registration complete). 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 17 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
 
 
 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 18 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
5.3. Secondary Endpoints 
The following secondary endpoints will be evaluated in all enrolled subjects: 
• 
Number of cases that are technically successful (successful completion of local registration) 
• 
In cases that are not technically successful, reason for incomplete local registration in each 
target lesion 
• 
Investigator confirmation that the catheter is in an “Adequate Periprocedural Location” (the 
location of the extended working channel with the proceduralist makes the decision that 
placement is adequate and clinically acceptable to proceed with tissue sampling based on 
location confirmation by CBCT). 
• 
Total procedure time 
• 
ENB procedure time 
• 
Total fluoroscopy time, as measured by the fluoroscopy system 
• 
Adequacy of the ENB-aided tissue sample for rapid on-site evaluation (ROSE) of cytologic 
samples by pathology (when applicable) 
• 
Histopathological call based on ROSE of the ENB-aided tissue sample (when applicable) 
• 
Final pathology results of the ENB-aided tissue sample 
• 
Biopsy tools used, tool order, number of passes, and diagnoses for each tool based on ROSE and 
final pathology of the ENB-aided sample 
In Technically Successful cases (local registration complete): 
• 
Percentage of cases in which the intended lesion is correctly identified (as opposed to a non-
target lesion or normal lung tissue) as indicated by the system software. 
• 
Relational Accuracy in cases in which the Intended lesion is targeted. 
5.4. Safety Endpoints 
The following safety endpoints will be evaluated in all enrolled subjects. These events will be evaluated 
for their relationship to the study device and study procedure, and classified according to Common 
Terminology Criteria for Adverse Events (CTCAE) Version 5. Adverse events and safety endpoints will be 
collected immediately post-procedure and at 7 days post procedure. 
• 
Incidence of all pneumothorax related to ENB index procedure 
• 
Incidence of CTCAE Grade ≥2 pneumothorax related to the ENB index procedure  
• 
Incidence of all bronchopulmonary hemorrhage related to ENB index procedure 
• 
Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage related to the ENB index 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 19 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
procedure  
• 
Incidence of CTCAE Grade ≥4 respiratory failure related to ENB index procedure  
In addition to the Safety Endpoints described above, all Adverse Events related to the superDimension™ 
navigation system, associated tools, or ENB procedure will be collected as described in Section 11. 
6. Study Design  
This post-market feasibility study is planned in up to 50 subjects meeting the inclusion criteria and 
undergoing elective ENB with the superDimension™ Navigation System v7.2 with Fluoroscopic 
Navigation Technology. The study will confirm the location accuracy of the optional local registration 
feature. Enrolled subjects will first undergo a standard ENB procedure to navigate to within 2.5 cm of 
the target lesion. Local registration with Fluoroscopic Navigation Technology will be conducted and 
fluoroscopy and CBCT scans will be used to document that the biopsy tool is correctly positioned in the 
target lesion in three dimensions. Details of the procedure are included in Section 9.7.3. Periprocedural 
endpoints will include confirmation of accurate positioning within the target lesion, technical success, 
relational accuracy, adequate periprocedural location, procedure time, adequacy of tissue capture for 
pathology, tool usage, and histopathological results, as described below. Safety will be evaluated 
immediately post-procedure and at 7 days post-procedure.  
6.1. Duration 
Assessments will occur at baseline, during the procedure, immediately post-procedure, and 7 days post 
procedure by telephone. 
Based on the expected enrollment rate of 5 subjects per site per month, the total duration of the study 
from first subject enrollment to last subject follow-up is expected to be approximately 6-8 months. 
6.2. Rationale  
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation 
System v7.2 with Fluoroscopic Navigation Technology.  
Several aspects of the study design make it desirable compared to other options. The v7.2 software 
includes an optional local registration feature intended to compensate for CT-to-body divergence 
though incorporation of additional fluoroscopic imaging data taken during the electromagnetic 
navigation procedure. The primary objective of this post-market feasibility study is to confirm the 
location accuracy of the local registration feature of the superDimension™ navigation system v7.2 in 
subjects undergoing lung lesion biopsy. This objective focuses on the intended use of the system at an 
immediate periprocedure timepoint, reducing the burden on subjects. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 20 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Enrollment of eligible subjects with minimal inclusion and exclusion criteria will ensure a more 
representative and generalizable sample. The targeted number of 50 subjects (25 per site) was chosen 
as the minimal number required to evaluate the technology at each site and is consistent with first 
experience studies evaluating the ENB technology.3-5, 7 
Design verification and validation test results provide reasonable assurance that the device conforms to 
the requirements for its indications for use and intended use. A thorough risk assessment has shown 
that the addition of the local registration feature does not significantly change the device risks. Design 
verification performed on the superDimension™ navigation system v7.2 confirmed that the 
superDimension™ navigation system met its product specification and system requirements. Regression 
testing was executed to verify the modifications did not impact unmodified software elements. Design 
validation was successfully performed under simulated use conditions by representative users from 
targeted user groups including qualified bronchoscopists and clinicians. Each user group performed 
typical use scenarios defined in the design validation protocol. In conclusion, the design validation study 
ensured that the superDimension™ navigation system v7.2 conformed to defined user needs and 
intended uses. 
Bench testing for the superDimension™ navigation system v7.2 consisted of verification of software and 
hardware elements of the product to confirm that the device performs as intended. Formal execution of 
software test cases, including regression testing, was completed in two test cycles to verify that the 
software meets the designated requirements. Hardware verification testing was performed on the only 
new hardware component of the system, the fiducial marker board, to demonstrate the component 
meets all design requirements. Overall, the results of the bench testing, including all related risk 
activities, showed that the superDimension™ navigation system v7.2 meets the design requirements for 
all hardware and software components and performs as intended. 
Prior clinical studies of the superDimension™ navigation system are described in Section 4.1.  
The current study will evaluate the location accuracy superDimension™ Navigation System v7.2 to 
determine if the local registration feature allows more accurate lesion targeting, with the same safety 
profile observed for previous superDimension™ navigation system versions. 
7. Product Description 
7.1. General 
superDimension™ navigation system v7.2 is a device that guides endoscopic tools to a target in or 
adjacent to the bronchial tree on a path identified by a previous CT scan. The superDimension™ 
navigation system v7.2 allows visualization of the target and the interior of the bronchial tree; 
placement of catheters in the bronchial tree; and placement of radiosurgical and dye markers into soft 
lung tissue to guide radiosurgery and thoracic surgery. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 21 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
The v7.2 software includes an optional local registration feature intended to compensate for CT-to-body 
divergence. Incorporation of additional fluoroscopic imaging data taken during the electromagnetic 
navigation procedure allows for 3D reconstruction of a small region of interest in the lung to 
compensate for possible CT-to-body divergence. Local registration is an optional feature and can be 
used at the physician’s discretion.  
The superDimension™ navigation system v7.2 includes a Procedure application software modification 
and one additional stand-alone hardware component, called a fiducial marker board. The local 
registration feature uses a fluoroscopic video taken during the procedure and a fiducial marker board to 
allow 3D reconstruction of a small region of interest. 
Reconstructing three-dimensional data from the multiple fluoroscopic 2D images requires knowing the 
position of the fluoroscope for every image relative to a fixed coordinate system. The fluoroscope 
projection angle is measured by detecting (through image processing) a grid of non-ferromagnetic 
spheres incorporated into the fiducial marker board 
.  
 
This grid of spheres, which is clearly visible under fluoroscopy, is used to determine the fluoroscope 
(camera) position and angle for each fluoroscopic video frame. The grid structure is laid out as a regular 
grid (15 mm separation in 2 dimensions) and treated as infinite in the fluoroscope plane. This means 
that the algorithm can use any visible portion of the grid to determine the angle. The grid is attached to 
the existing location board in a way that aligns the ENB coordinate system. The location board is part of 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 22 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
the localization system that is placed underneath the patient bed mattress. Solving for the fluoroscope 
position and angle relative to the grid, provides the exact orientation for the fluoroscope in the ENB 
antenna coordinates. This enables the system to create a 3D reconstruction aligned with the ENB 
coordinate system. Therefore, the ENB catheter position relative to the target in the ENB coordinates 
system is known and adjusted in the ENB coordinate system accordingly. 
7.2. Dosage Form and Route of Administration 
Not Applicable. 
7.3. Manufacturer 
The superDimension™ Navigation System v7.2 with Fluoroscopic Navigation Technology is manufactured 
by Covidien llc, an indirect wholly owned subsidiary of Medtronic plc. 
7.4. Packaging 
The device includes hardware, Planning and Procedure software, disposable sterile devices, and 
disposable non-sterile components. 
7.5. Intended Population 
The superDimension™ Navigation System v7.2 with Fluoroscopic Navigation Technology is indicated for 
patients when it is necessary to guide an endoscopic tool in the pulmonary tract when the indications 
for such an examination are present in the patient. Not for pediatric use. 
7.6. Equipment 
Equipment for the study includes: 
• 
CBCT system, such as the Philips Allura Xper FD20 Fluoroscopy System  
• 
The superDimension™ navigation system v7.2 (Figure 4): Includes a Procedure application 
software modification and one additional stand-alone hardware component, called a fiducial 
marker board. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 23 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Software
Hardware
Local Registration  Module
Edge / LG
IPC
Mouse
Keyboard
Touch Monitor
Foot Pedal
PST
Location Board
Key
No change 
Planning
Procedure – Minor change 
Data interface with the local 
registration 
 feature
Graphic card
Video card
Fiducial Marker 
Board 
Minor change
New
LSS
superDimension Navigation System
 
Figure 4. superDimension™ navigation system v7.2 components 
7.7. Product Use 
The local registration feature requires a fluoroscopic video focused on the region of interest taken at the 
time of the ENB procedure. The fluoroscopic video is sent to the superDimension™ console through the 
video input channel. The physician then identifies or marks the tip of the catheter and the target. To 
facilitate this marking, the module provides visualization of soft tissue in the lung by an image 
processing mechanism. The image processing reconstructs a 3D volume and enables image slice display 
throughout that volume. As part of the visualization mechanism, each point in each image is associated 
with a point in three-dimensional space created from the fluoroscopic video. 
Once the three-dimensional location of the catheter and target are established, the local registration 
feature performs an update of the catheter position in the ENB system. The update is based on the 
three-dimensional position of the catheter relative to the target obtained from the reconstructed three-
dimensional data. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 24 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
The ENB procedure consists of the following primary procedure steps (Figure 5). 
This is a brief explanation of the proposed standard-of-care use and is not the procedure  
to be used in the current clinical study. 
 
 
Figure 5: ENB Procedure Steps 
 
A brief explanation of the ENB procedure steps is provided below. 
1. Start Procedure Application:  The physician logs onto the system and selects the procedure 
button from the home screen. 
2. Setup:  During setup, the physician verifies that the equipment and room are correct as 
previously qualified. The physician also loads the specific patient plan created in the planning 
software.  
3. Registration:  During the registration, the locatable guide is placed inside the extended working 
catheter which is then inserted through the bronchoscope channel. The locatable guide 
contains a sensor in the tip that reads the magnetic field generated by the localization system. 
This allows the system to determine the locatable guide’s position. During registration, the 
locatable guide gathers survey data from the patient which is matched with the three-
dimensional map generated from the CT scan during planning. When the registration is 
completed successfully, the physician can begin navigation. 
4. Navigation:  During navigation, the physician uses the images of the patient’s lungs displayed in 
the system views on the computer screen to steer the locatable guide catheter to the 
predetermined target. 
5. Local Registration:  Once the physician is within 2.5 cm of the target, the local registration 
feature can be launched. If desired, the physician selects the launch button on the screen to 
initiate the local registration process. The purpose of local registration is to account for CT-to-
body divergence. CT-to-body divergence exists where the patient’s anatomy does not perfectly 
align with the three-dimensional CT. Because the inhale level during the CT scan is different 
than during the procedure, the lung’s volume and shape are different. Other factors resulting in 
deformation or divergence from the original CT may include the presence and push by the 
bronchoscope or catheter, airway muscle’s reaction to sedation or anesthesia, a different 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 25 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
patient position, bed curvature, and anatomical changes. The software adjusts for this as much 
as possible during the initial registration procedure in step 3 by using an algorithm to perform a 
best fit alignment to the entire patient’s lungs. Since it is a best fit algorithm, some deviation 
between the model and actual anatomy can still exist and is called CT-to-body divergence. 
6. The local registration process focuses on a small region of interest around the target and 
refines the three-dimensional model based on the fluoroscopic image data. This takes into 
consideration any changes in the patient positioning or other changes compared to the CT 
scan. Because the data is taken at the time of the procedure and covers a specific region of the 
lung, the system can create a more precise model around the target thus minimizing local CT-
to-body divergence. 
7. When the local registration feature is selected, the software guides the physician through the 
following steps: 
a. Setup  
b. Image capture using the fiducial marker board to determine angle 
c. Catheter and target marking 
d. Confirmation of catheter and target marking 
e. Once the physician has confirmed the catheter and target marking, the local registration 
feature is exited, the catheter position is updated based on the local registration, and 
the ENB procedure continues exactly as in the predicate by finalizing the navigation to 
the target. The physician may also choose to disregard the update and revert to the 
previous (initial) registration or to repeat the local registration feature.  
8. End Procedure:  Once the physician has completed navigation and performed any additional 
fiducial marker placement or biopsies, the extended working channel is removed and the 
procedure completed. 
7.8. Product Training Requirements 
Only a qualified bronchoscopist (i.e., physician) may navigate with the superDimension™ navigation 
system. A clinician, under the direct supervision of the bronchoscopist, may assist in the navigation 
system setup and provide care to the patient during the ENB procedure. This may be a hospital or clinic 
employee that has received system training.  
In order to use the local registration feature, a service representative must visit the facility and verify 
that there is a compatible fluoroscope, attach the fiducial marker board, install software, and ensure 
that the system performs as intended. Once set up, the module is used during a standard procedure 
when the locatable guide is within 2.5 cm from the target. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 26 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Each investigator participating in the clinical trial and the associated clinical study staff will receive 
training on the clinical protocol, as well as the ENB procedure utilizing the superDimension™ navigation 
system v7.2. Physicians must demonstrate proficiency with the superDimension™ navigation system 
v7.2. 
7.9. Product Receipt and Tracking 
All products used in this study will be commercially available, and therefore do not require receipt and 
tracking information to be collected. This does not exclude the collection of Lot and/or Serial Numbers 
for the purpose of post market vigilance activities. 
7.10. Product Storage 
All products used will be commercially available, and are expected to be stored per the site’s standard 
practice for medical equipment. 
7.11. Product Return 
Not applicable, all study equipment to be utilized will be commercially available. 
7.12. Product Accountability  
Not applicable, all study equipment to be utilized will be commercially available. 
7.13. Intended Claims 
Claims and intended performance of the study product (including aspirational claims) to be verified by 
the study: 
• 
Ability to compensate for localization divergence (induced by CT-to-body divergence) 
• 
Ability to locally register and enhance lesion visibility 
• 
Provide enhanced visualization 
• 
Provide updated catheter position relative to the nodule once nodule location is confirmed 
8. Selection of Subjects 
8.1. Study Population 
This study will be conducted in subjects over the age of 18 undergoing elective biopsy of lung lesions 
greater than 10 mm in diameter. Additional inclusion/exclusion criteria are listed below. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 27 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
8.2. Subject Enrollment 
This study will enroll up to 50 subjects meeting the inclusion criteria, with a maximum of 25 subjects per 
site. Up to 5 clinical sites in the United States are planned. 
Subjects meeting the inclusion/exclusion criteria below will be enrolled. Following signing the informed 
consent form (ICF), the point of enrollment is defined as the entry of the first locatable guide. 
The ENB procedure will be performed per the System User Manual, applicable product instructions for 
use (IFU) and the institution’s standard practice. Subjects will be considered for the study if they meet 
specified inclusion criteria and none of the exclusion criteria. The criteria for enrollment must be 
followed explicitly. 
8.2.1. 
Roll-in Subjects 
A maximum of five roll-in cases will be allowed per investigator. The purpose of the roll-in cases is to 
provide consistency in the physician user base within the study and optimize procedural methods. Roll-
in subjects will be considered study participants and will complete all protocol-required procedures and 
exams. An interim analysis will be conducted after the completion of roll-in enrollment to evaluate study 
workflow and data validity. The protocol will be amended if necessary. 
8.3. Inclusion Criteria 
1. Subject presents with lung lesion(s) greater than 10 mm in diameter amenable to evaluation by 
ENB at the time of evaluation 
2. Lesion is intended to be biopsied by the participating investigator 
3. Subject is willing and able to provide informed consent to participate in the study 
4. Subject is a candidate for an elective ENB procedure 
5. Subject is over the age of 18 
8.4. Exclusion Criteria 
1. Central lesions that are not visible endobronchially or could be reached by a flexible 
bronchoscope or endobronchial ultrasound (EBUS) without the utilization of ENB 
2. Lesions within 10 mm of the diaphragm 
3. The subject is unable or unwilling to comply with study follow-up schedule 
4. The subject has participated in an investigational drug or device research study within 30 days 
of enrollment that would interfere with this study 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 28 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
5. Female subjects who are pregnant or nursing as determined by standard site practices  
9. Study Procedures  
Below is a description of the procedures that the subject will undergo during the clinical study. 
9.1. Schedule of Events 
Variables to be collected, follow-up visit schedule, and tests to be performed at each visit are described 
in Table 1 below. 
Table 1. Schedule of Events 
 
Baseline 
(Day - 30 to Day 0) 
During and 
immediately post-
procedure 
(Day 0) 
7 days Post-
Procedure 
(window = 4-7 days) 
Informed consent 
X 
 
 
Eligibility criteria 
X 
 
 
Demographics 
X 
 
 
Medical history 
X 
 
 
Procedural information 
 
X 
 
Lesion characteristics 
X 
X 
 
Adverse event assessment 
 
X 
X 
Biopsy results 
 
X 
X 
 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 29 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
9.1.1. 
Overview of Study Procedures 
Figure 6. Procedure Steps 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 30 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
9.2. Subject Screening  
A baseline visit will be performed within 30 days prior to the scheduled procedure to assess study 
eligibility. Consented subjects will be considered for the study if they meet specified inclusion criteria 
and none of the exclusion criteria. The criteria for enrollment must be followed explicitly. 
Subjects who provide study consent, but then are determined to be ineligible prior to the ENB 
procedure will be considered Screen Failures and will not require additional study follow-up visits. The 
reason for the Screen Failure will be clearly documented on the applicable electronic case report forms 
(eCRFs). Screen Failures will not be counted towards the number of study subjects. 
9.3. Prior and Concomitant Medications 
All prior and concomitant medications should be managed according to standard-of-care.  
9.4. Subject Consent 
Subjects will be approached to obtain written informed consent prior to any institution non-standard-of-
care assessments or study specific data being collected. The purpose of the study and the benefits and 
risks of participating in the study will be explained to the subject and the consent process must be 
documented accordingly. 
Subjects will be informed that their participation in this study is voluntary and that they may refuse to 
participate or discontinue from the study at any time. Additionally, subjects will be informed that 
despite signing informed consent, the screening assessments may demonstrate the subject is not a 
suitable candidate for the study and may be withdrawn. Subjects will be given the opportunity to ask the 
investigator questions so that they are adequately informed about the research.  
After being informed of the nature of the study, subjects who agree to study participation must sign a 
written ICF that has been approved by the appropriate Institutional Review Board (IRB) or Ethics 
Committee (EC) of the respective clinical site. A copy of the signed ICF must be provided to the subject. 
For this study, the subject must sign and date the ICF themselves. The use of Legally Authorized 
Representatives, Healthcare Proxies or any other means of representation will not be permitted. 
If new information becomes available that may affect a subject’s decision to continue to take part in the 
study, this information will be discussed with the subject. 
The principal investigator or his/her authorized designee must conduct the informed consent process.  
9.5. Randomization and Treatment Assignment 
Not applicable. There are no treatment arms or randomizations required for this study. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 31 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
9.6. Medication Compliance 
Not applicable. There are no required medications or medication protocols for this study. 
9.7. Assessment of Efficacy 
9.7.1. 
Baseline 
The following assessments will be performed within 30 days prior to the scheduled ENB procedure: 
• 
Signed informed consent 
• 
Eligibility criteria 
• 
Subject demographics 
• 
Medical history 
9.7.2. 
Procedure Day 
The following procedures and assessments will be performed on the day of the index procedure (Day 0): 
• 
Lesion characteristics (e.g., size, location, morphology) 
• 
Procedural information (e.g., technical success, procedure time, biopsy tools, primary and 
secondary endpoints). 
9.7.3. 
Procedure Details 
Details of the index procedure are given below (see also Figure 6). 
1. Begin ENB per standard practice. 
2. Complete automatic registration and navigate to a position that is within 2.5 cm of the target 
index lesion. 
3. Lock LG in place and conduct local registration with Fluoroscopic Navigation Technology 
(without moving the catheter). 
4. Complete a CBCT scan to document the correct location (prior to any movement of the LG).  
5. Complete navigation and position the catheter as appropriate based on the local registration 
correction. 
6. Conduct a second local registration. 
7. Conduct a second CBCT. 
8. Advance the first biopsy tool. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 32 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
9. Once in place to biopsy, capture fluoroscopy video sweep with a tool in place (Fluoro “Tool in 
Lesion”). “In Place” is intended to mean in the location at which tissue sampling would occur. 
10. Complete a CBCT scan to confirm that the biopsy tool is accurately positioned in three 
dimensions within the lesion (CBCT “Tool in Lesion”).  
11. If available, radial endobronchial ultrasound (rEBUS) may be used to reconfirm the location 
12. Complete biopsy sampling per standard size practices. 
13. Complete lymph node sampling per standard site practices. 
9.7.4. 
Study Completion 
Subjects will complete the study at the completion of the 7-day post-procedure visit. No additional care 
will be provided to study subjects after completion of the study with respect to this clinical investigation 
plan (CIP). Standard of care should continue. The reporting window for the 7-day follow-up is 4-7 days. 
9.8. Assessment of Safety 
Adverse events will be collected after the ENB index procedure has been initiated (defined as 
introduction of the locatable guide or extended working channel into the subject). Adverse events will 
be collected immediately post-procedure and at 7-day post-procedure visit, with a window of 4-7 days 
post-procedure for the 7-day phone call. 
The following safety endpoints will be evaluated in all enrolled subjects. These events will be evaluated 
for their relationship to the study device and study procedure, and classified according to CTCAE Version 
5. 
• 
Incidence of all pneumothorax related to ENB index procedure 
• 
Incidence of CTCAE Grade ≥2 pneumothorax related to the ENB index procedure  
• 
Incidence of all bronchopulmonary hemorrhage related to ENB index procedure 
• 
Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage related to the ENB index 
procedure  
• 
Incidence of CTCAE Grade ≥4 respiratory failure related to ENB index procedure  
In addition to the Safety Endpoints described above, all Adverse Events related to the superDimension™ 
navigation system, associated tools, or ENB procedure as described in Section 11. 
9.9. Recording Data 
This study will utilize an eCRF. The eCRF will be used to capture the required data elements. Medical and 
study records, rather than eCRFs, will serve as the source documentation. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 33 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
9.10. Deviation Handling 
The Principal Investigator must make every effort to follow the CIP, unless the deviation is necessary in 
an emergent situation to protect the rights, safety and/or wellbeing of the subject. Deviations from the 
CIP will be collected on a Protocol Deviation CRF and reviewed with the Principal Investigator to ensure 
compliance.  
The investigator must notify Medtronic and the reviewing IRB/EC of any deviation from the 
Investigational Plan when specific to the protection of the life or physical well-being of a subject in an 
emergency. Such notice must be given as soon as possible, but in no event later than five (5) working 
days after the emergency has occurred.  
If a pattern of non-compliance is noted, the study manager will determine the course of action to take, 
such as root cause, review relevant CIP procedures and as applicable retrain and verify understanding of 
the issue in question. This will be documented in the Study Master Files. In the case of repeated or 
serious non-compliance, the Sponsor reserves the right to disqualify the offending site. 
9.11. Subject Withdrawal or Discontinuation  
Subjects may voluntarily withdraw themselves from the study if they no longer wish to have their study 
related information used. Additionally, the Principal Investigator may withdraw or choose not to enroll a 
subject if they feel they do not meet the CIP defined Inclusion and Exclusion Criteria or if it is in the best 
medical interest of the subject in question. 
In cases of voluntary subject withdrawal, all data collected from the time of Informed Consent to the 
time of Voluntary withdrawal may be used. Additionally, subjects who withdraw or discontinue will not 
be replaced. Enrollment will continue as per CIP definitions up to the predefined maximum number of 
subjects. 
The reason for study exit of all enrolled subjects will be documented on the applicable electronic case 
report form (eCRF). In the event the subject withdraws consent during the study, the date of withdrawal 
will be documented. If the study investigator voluntarily removes a subject from further study 
participation, supporting documentation must be in place for the rationale and date of removal. Every 
attempt will be made to contact subjects who are noncompliant. Subjects will be considered lost to 
follow-up once the following steps have been taken: 
• 
Three phone calls should be made to the subject. Each attempt should be clearly documented in 
the source documents and the response or lack thereof should be captured. 
• 
If there is no response to the phone calls, then certified letter should be written to the subject. A 
copy of the letter should be retained in the subject’s source document. 
• 
After a period of one (1) week following completion of the above actions, the subject will be 
considered Lost to Follow-up. The sponsor should be notified and the Study Exit form should be 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 34 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
completed.  
10. Risks and Benefits 
10.1. Potential Risks 
All devices utilized in this study are commercially available. There are no anticipated risks related to 
inclusion of subjects in this clinical study above and beyond anticipated risks related to any ENB 
procedure. All records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. Subject names will be kept 
confidential.  
Addition of the Fluoroscopic Navigation Technology to the superDimension™ Navigation System is not 
expected to increase the risk of the device beyond the risks previously reported for superDimension™ 
Navigation System v7.1. Potential risks of the use of the superDimension™ Navigation System for ENB 
procedures have been evaluated in the superDimension™ navigation system v7.2 Use Failure Modes and 
Effects Analysis (UFMEA; DHA00036 Rev B, with unchanged risks from DHA00027 Rev I), as well as in the 
NAVIGATE Clinical Trial Medical Device Reporting (MDR) Reportable Event Trend & Risk Analysis Report 
for the superDimension™ Navigation System Version 7.2 (DGR00462, Effective28-Sep-2017). 
10.1.1. 
Summary MDR Reportable Event Trend & Risk Analysis Report  
The NAVIGATE clinical study (study number NCT02410837) first subject enrollment occurred on April 16, 
2015. The objective of the study is to evaluate outcomes following electromagnetic navigation 
bronchoscopy (ENB) procedures using the superDimension™ navigation system.39 
An analysis was performed on the MDR reportable events associated with the NAVIGATE study to 
determine how this information relates to the superDimension™ navigation system v7.2. In this analysis 
the MDRs associated with NAVIGATE were reviewed for any notable trends and new adverse effects. 
The reporting period for the analysis ranged from April 2015 through July 2017. During this time there 
have been 291 reportable events reported by Covidien llc to the FDA. This includes 130 deaths, 3 
malfunctions, and 158 serious injuries. The majority of deaths were determined to be primarily related 
to the patient’s condition with no allegations against a Covidien llc Interventional Lung Solutions (ILS) 
device. The overall adverse event reporting rate for the ILS group during the time period was 1.16% 
(including the MDRs associated with NAVIGATE). 
Risk management procedures and supporting documentation were updated to align adverse effects and 
occurrence rates observed in the NAVIGATE MDR data. Furthermore, a field experience analysis was 
performed for the superDimension™ navigation system v7.2 to determine any additional design inputs 
during development. 
A paper published in April 2017 documents the results of the first 1,000 subjects enrolled in the 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 35 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
NAVIGATE study after one-month follow-up.37 The interim data provides an early look at typical patient 
and lesion characteristics and procedural standard-of-care. Data demonstrated low adverse event rates 
in a generalizable population across diverse practice settings. 
Overall, no notable trends were identified based on the analysis of the NAVIGATE study MDRs. The 
report summarizing the first 1,000 subjects at one-month follow-up further demonstrates a safe patient 
profile for the superDimension™ navigation system.37 The data generated from the NAVIGATE study was 
taken into consideration and incorporated during the development of the superDimension™ navigation 
v7.2 system. 
In the majority of cases, the root cause could not be determined as the device was either not returned 
for analysis or no issues were found during investigation (127). Some cases were attributed to the ENB 
procedure (15) and patient condition (1) with no allegations against ILS devices or were attributed to 
non-ILS devices (11).  
The most common serious injury reported included pneumothorax (72), bleeding (38), and medical 
complications (31). Pneumothorax and bleeding are known complications associated with 
electromagnetic navigation systems. A further breakdown of adverse events by the subject device and 
investigation results is provided below in Table 2. 
Please refer to the most current version of the Reportable Event Trend & Risk Analysis Report for 
additional information. 
  

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 36 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Table 2. Event Type by Device 
Subject Device 
Event Type 
Internal Investigation Results 
Total 
System Console 
Pneumothorax 
Inconclusive – no anomalies identified (28) 
40 
Related to procedure (4) 
Related to non-superDimension Tool (7) 
Investigation in process (1) 
Bleeding 
Inconclusive – no anomalies identified (14) 
19 
Related to non-superDimension Tool (4) 
Patient Condition (1) 
Pneumomediastinum 
Inconclusive – no anomalies identified (3) 
3 
Medical 
Complication 
Inconclusive – no anomalies identified (22) 
27 
Related to procedure (5) 
Respiratory 
Complication 
Inconclusive – no anomalies identified (11) 
14 
Related to procedure (3) 
GenCut Core 
Biopsy Tool 
Pneumothorax 
Inconclusive – no anomalies identified (1) 
2 
Related to procedure (1) 
Bleeding 
Inconclusive – no anomalies identified (2) 
4 
Related to procedure (1) 
Inconclusive – no device information provided (1) 
Biopsy Forceps 
Pneumothorax 
Inconclusive – no anomalies identified (9) 
9 
Bleeding 
Inconclusive – no anomalies identified (2) 
7 
Inconclusive – no device information provided (3) 
Investigation in process (2) 
Biopsy Needle 
Pneumothorax 
Inconclusive – no anomalies identified (5) 
7 
Inconclusive – no device information provided (1) 
Investigation in process (1) 
Bleeding 
Inconclusive – no anomalies identified (4) 
5 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 37 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Table 2. Event Type by Device 
Subject Device 
Event Type 
Internal Investigation Results 
Total 
Inconclusive – no device information provided (1) 
Medical 
Complication 
Inconclusive – no anomalies identified (1) 
1 
Cytology Brush 
Pneumothorax 
Inconclusive – no anomalies identified (7) 
12 
Inconclusive – no device information provided (5) 
Bleeding 
Inconclusive – no anomalies identified (1) 
3 
Inconclusive – no device information provided (2) 
Extended 
Working 
Channel 
Pneumothorax 
Related to procedure (1) 
1 
Medical 
Complication 
Inconclusive – no anomalies identified (2) 
3 
Inconclusive – no device information provided (1) 
Fiducial Marker 
Pneumothorax 
Inconclusive – no anomalies identified (1) 
1 
 
 
Total 
158 
10.1.2. 
Study-related Imaging 
There are risks associated with the use of x-ray fluoroscopy and CBCT imaging for this study.  
A milliSievert (mSv) is a unit of radiation dose. The average effective radiation dose during a typical 
bronchoscopy procedure with fluoroscopic guidance is approximately 0.5 mSv40 up to 2 mSv per scan. 
The typical radiation dose from a chest CBCT scan is estimated at 0.98-1.15 mSv.41 Up to approximately 
3 fluoroscopy sweeps and 3 CBCT scans will be conducted during the study procedure. Thus, the total 
radiation exposure from this study is estimated at up to 9-10 mSv. It should be noted that radiation dose 
will vary based on the type of imaging system used and the size of the patient. 
For comparison, the average dose from natural sources of radiation is approximately 3 mSv per year 
from natural background radiation, such as radon and cosmic rays. In higher elevation areas the 
background exposure can be as high as 10 mSv per year. The annual allowable dose for radiation 
workers (e.g., x-ray technicians) is 50 mSv. 
The probability for absorbed x-rays to induce cancer or heritable mutations leading to genetically 
associated diseases in offspring is thought to be very small for radiation doses of the magnitude that are 
associated with CT procedures. For any one person, the risk of radiation-induced cancer is much smaller 
than the natural risk of cancer. However, the risk of harmful effects may increase if a patient is exposed 
to additional procedures that involve radiation such as x-rays or additional CT scans required during 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 38 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
standard of care. 
10.2. Potential Benefits 
Outside of the normal ENB procedure, the study may or may not be of benefit to the study subjects. The 
data collected from this study will help to collect new information on the accuracy of the Fluoroscopic 
Navigation Technology feature and future system enhancements. 
10.3. Risk-Benefit Rationale 
Every effort will be made to minimize the risks discussed in Section 10.2, as these risks are standard for 
this procedure. There will be minimal change to the execution of the ENB procedure as it relates to the 
planning, ENB guidance of associated procedural biopsy tools or method of sampling. It is more likely 
that the addition of the fiducial board will improve visibility and provide a reference of measurement for 
areas of interest. 
Additional design elements to reduce risk and burden to the subject are described in Section 6.2. 
11. Adverse Events and Device Deficiencies 
11.1. Definitions/Classifications 
Adverse event definitions used in this study are based on ISO 14155:2011 (Clinical Investigation of 
Medical Devices for Human Subjects -- Good Clinical Practice; 
https://www.iso.org/obp/ui/#iso:std:iso:14155:ed-2:v1:en), which is aligned with MEDDEV 2.7/3 
Revision 3, May 2015 (Guidelines on Medical Devices, Clinical Investigations: Serious Adverse Event 
Reporting).  
Adverse events will be collected after the point of enrollment (defined as introduction of the locatable 
guide into the subject). Adverse events (AEs) will be monitored until a subject completes the study. Any 
unresolved procedural or device related events that are still ongoing past study exit will be monitored by 
the physician per their institutional standard of care.  
In addition to the Safety Endpoints described in Section 5.4, all Adverse Events related to the 
superDimension™ navigation system, associated tools, or ENB procedure. 
Anticipated adverse events are listed in Section 10.1. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 39 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
11.1.1. 
Adverse Event (AE) 
An Adverse Event is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects whether or not related to the 
investigational medical device.  
NOTE 1:  This definition includes events related to the superDimension™ Navigation System v7.2 with 
Fluoroscopic Navigation Technology and all superDimension™ tools and accessories. 
NOTE 2:  This definition includes events related to the procedures involved, including bronchoscopy and 
sedation. 
Events occurring in users or other persons related to the medical device will not be collected for the 
purposes of this study. 
11.1.2. 
Serious Adverse Event (SAE) 
For the purposes of this study, a Serious Adverse Event is an adverse event that has 
1. Led to death, 
2. Led to serious deterioration in the health of the subject, that either resulted in 
a. A life-threatening illness or injury, or 
b. A permanent impairment of a body structure or a body function, or 
c. In-patient or prolonged hospitalization, or 
d. Medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
NOTE 1: This includes device deficiencies that might have led to a serious adverse event if a) suitable 
action had not been taken or b) intervention had not been made or c) if circumstances had been less 
fortunate. These are handled under the SAE reporting system.  
NOTE 2: Planned hospitalization for a pre-existing condition, or a procedure required by the clinical 
investigational plan, without serious deterioration in health, is not considered a serious adverse event. 
11.1.3. 
Adverse Device Effect (ADE) 
An Adverse Device Effect is an adverse event related to the use of an investigational medical device. 
NOTE 1:  This definition includes adverse events resulting from insufficient or inadequate instructions for 
use, deployment, implantation, installation, or operation, or any malfunction of the investigational 
medical device. 
NOTE 2:  This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 40 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
11.1.4. 
Serious Adverse Device Effect (SADE) 
A Serious Adverse Device Effect is an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event. 
11.1.5. 
Unanticipated Serious Adverse Device Effect (USADE) 
An Unanticipated Serious Adverse Device Effect (USADE) is defined as serious adverse device effect 
which by its nature, incidence, severity or outcome has not been identified in the current version of the 
risk analysis report. 
11.1.6. 
Device Deficiency 
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or 
performance. 
Note: Device deficiencies include malfunctions, use errors, and inadequate labelling. 
11.1.7. 
Adverse Event Relationship Classification 
Causality assessments define the relationship between the use of the medical device (including the 
procedure) and the occurrence of each adverse event. During causality assessment activity, clinical 
judgment shall be used and the relevant documents, such as the MDR Reportable Event Trend & Risk 
Analysis Report shall be consulted, as all the foreseeable serious adverse events and the potential risks 
are listed and assessed there. The presence of confounding factors, such as concomitant 
medication/treatment, the natural history of the underlying disease, other concurrent illness or risk 
factors shall also be considered. 
Each AE and SAE will be classified according to five different levels of causality. The following definitions 
will be used to assess the relationship of the serious adverse event to the investigational medical device, 
accessory devices, or procedures: 
• 
Not related:  Relationship to the device or procedures can be excluded when: 
o the event is not a known side effect of the product category the device belongs to or of 
similar devices and procedures 
o the event has no temporal relationship with the use of the investigational device or the 
procedures; 
o the serious event does not follow a known response pattern to the medical device (if 
the response pattern is previously known) and is biologically implausible; 
o the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or increase 
of the level of activation/exposure), do not impact on the serious event; 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 41 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
o the event involves a body-site or an organ not expected to be affected by the device or 
procedure; 
o the serious event can be attributed to another cause (e.g. an underlying or concurrent 
illness/ clinical condition, an effect of another device, drug, treatment or other risk 
factors); 
o the event does not depend on a false result given by the investigational device used for 
diagnosis, when applicable; 
o harms to the subject are not clearly due to use error; 
o In order to establish the non-relatedness, not all the criteria listed above might be met 
at the same time, depending on the type of device/procedures and the serious event. 
• 
Unlikely: The relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by another cause, but additional information may be obtained. 
• 
Possible:  The relationship with the use of the investigational device is weak but cannot be ruled 
out completely. Alternative causes are also possible (e.g. an underlying or concurrent illness/ 
clinical condition or/and an effect of another device, drug or treatment). Cases were relatedness 
cannot be assessed or no information has been obtained should also be classified as possible. 
• 
Probable:  The relationship with the use of the investigational device seems relevant and/or the 
event cannot reasonably be explained by another cause, but additional information may be 
obtained. 
• 
Causal relationship: The serious event is associated with the investigational device or with 
procedures beyond reasonable doubt when: 
o the event is a known side effect of the product category the device belongs to or of 
similar devices and procedures; 
o the event has a temporal relationship with investigational device use/application or 
procedures; 
o the event involves a body-site or organ that 
o the investigational device or procedures are applied to; 
o the investigational device or procedures have an effect on; 
o the serious event follows a known response pattern to the medical device (if the 
response pattern is previously known); 
o the discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the serious event (when clinically feasible); 
o other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and 
an effect of another device, drug or treatment) have been adequately ruled out; 
o harm to the subject is due to error in use; 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 42 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
o the event depends on a false result given by the investigational device used for 
diagnosis, when applicable; 
o In order to establish the relatedness, not all the criteria listed above might be met at the 
same time, depending on the type of device/procedures and the serious event. 
Events will be distinguished between the serious adverse events related to the device and those related 
to the procedures (any procedure specific to the clinical investigation). An adverse event can be related 
both to procedures and the device. Complications of procedures are considered not related if the said 
procedures would have been applied to the patients also in the absence of device use/application. 
In some particular cases the event may be not adequately assessed because information is insufficient 
or contradictory and/or the data cannot be verified or supplemented. The sponsor and the Investigators 
will make the maximum effort to define and categorize the event and avoid these situations. Where the 
sponsor remains uncertain about classifying the serious event, it should not exclude the relatedness and 
classify the event as “possible”. 
11.1.8. 
Adverse Event Outcome Classification 
Outcome of the event will be defined according to the following:  
• 
Fatal:  If death was possibly, probably, or causally related to the event 
• 
Not recovered / not resolved:  Subject has exited the study and the AE is ongoing and not 
expected to resolve 
• 
Recovered / resolved:  The event has fully resolved prior to study exit 
• 
Recovered / resolved with sequelae:  The event has resolved prior to study exit, but retained 
pathological conditions resulting from the prior disease or injury  
• 
Recovering / resolving:  The subject has exited the study and the AE is ongoing but expected to 
resolve 
• 
Unknown:  The subject has exited the study and the AE outcome is unknown 
11.2. Reporting of Adverse Events 
Assessment of the occurrence of an AE will be based on changes in the subject’s physical examination, 
laboratory results, and/or signs and symptoms. AEs will be monitored until a subject completes the 
study. Any unresolved procedural or device related events that are still ongoing past study exit will be 
monitored by the physician per their institutional standard of care. AEs will be documented in the 
applicable source documentation and reported on an AE eCRF. To the extent possible, the event to be 
recorded and reported is the event diagnosis as opposed to event outcome (e.g., death) or symptoms 
(e.g., fever, chills, nausea and vomiting in the presence of a clinically diagnosed infection is to be 
reported as infection only). 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 43 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
The following should not be considered an AE: 
• 
A condition requiring a preplanned procedure unless the condition worsened since enrollment 
• 
A preexisting condition found as a result of screening, unless the condition has worsened since 
enrollment. 
For purposes of this protocol, the following occurrences are considered to be expected observations 
following bronchoscopy procedures (primarily associated with anesthesia) and will not be considered 
AEs, as long as the event is not associated with significant sequelae, does not prolong hospitalization, 
and responds to standard medical therapy:  
• 
procedure transient nausea determined to be procedure related and resolving within 4 days 
after the procedure  
• 
Post procedure transient emesis determined to be procedure related and resolving within 3 
days after the procedure  
• 
Post procedure constipation, determined to be procedure and/or medication related 
• 
Post procedure pain that the study investigator considers common and expected post procedure 
All responses to the above events that require treatment beyond the institution’s standard procedures 
will be reported as AEs. 
11.2.1. 
Notification to Authorities 
The following events are generally considered reportable during the course of this study and should be 
reported within the timeframes outlined in Table 3: 
• 
any AE or SAE 
• 
any Device Deficiency  
• 
new findings/updates in relation to already reported events 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 44 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
Table 3. Reporting of Adverse Events 
Type 
Report to 
Reporting Timeframe (from time of 
learning of event) 
Device Deficiency  
Sponsor 
Not to exceed 10 working days  
AE 
Sponsor 
Not to exceed 10 working days 
IRB/EC 
Per IRB/EC reporting requirements 
SAE 
Sponsor 
Not to exceed 10 working days 
IRB/EC 
Per IRB/EC reporting requirements 
Events will be reviewed by sponsor or designee to determine any reporting obligations to National 
Competent Authorities and IRB/EC.  
Any Adverse Event will be recorded on the Adverse Event CRF. 
12. Data Review Committees  
There will be no Data Monitoring Committee, Clinical Events Committee or Adverse Events Advisory 
Committee needed for this post-market feasibility study. 
13. Statistical Design and Methods 
All statistical analyses will be performed using Statistical Analysis System (SAS) for Windows (version 9.2 
or higher, SAS Institute Inc. Cary, NC) or other widely accepted statistical or graphical software.  
Descriptive statistics will be used to present the data and to summarize the results. Continuous variables 
will be summarized with number of subjects (n), mean, standard deviation, median, and ranges. 
Categorical variables will be summarized by frequencies and percentages. 
The sample size of this feasibility study is not based on power calculations of a statistical hypothesis test. 
The following endpoints will be evaluated in Technically Successful cases (those with local registration 
complete): 
• 
Primary Endpoint:  The measured ability of the superDimension™ Navigation System v7.2 with 
Fluoroscopic Navigation Technology to place the center of the virtual navigation target (green 
ball) on the intended target lesion as confirmed by CBCT. 
• 
Secondary Endpoint:  Percentage of cases in which the intended lesion is correctly identified (as 
opposed to a non-target lesion or normal lung tissue) as indicated by the system software. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 45 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
• 
Secondary Endpoint:   Relational Accuracy in cases in which the Intended lesion is targeted. 
All other endpoints and safety outcomes will be evaluated in all enrolled subjects. 
The following analyses will be conducted: 
• 
Interim Analysis:  Will be conducted after the first 5 procedures have been completed for the 
purpose of evaluating workflow and data validity. 
• 
Final Analysis: Will be conducted after all subjects have completed the procedure for the 
purpose of evaluating the primary and secondary endpoints. 
There are no pre-planned subgroup analyses. Any post-hoc subgroup analyses will be exploratory in 
nature for the purpose of evaluating the safety and performance of the study device under various 
clinical conditions. 
Due to the post-market and observational nature of the study, no imputation is planned for missing data 
in the primary and secondary endpoints, if any. All available data from enrolled subjects will be 
reported. 
A detailed Statistical Analysis Plan (SAP) will be prepared prior to data analysis.  
Any deviations from this analysis plan will be documented in the final clinical study report.  
14. Ethics 
14.1. Statement(s) of Compliance  
This clinical investigation will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, as well as with ISO 14155:2011 (Clinical Investigation of Medical 
Devices for Human Subjects – Good Clinical Practice) and the International Conference on 
Harmonisation (ICH) of Technical Requirements For Registration of Pharmaceuticals For Human Use, ICH 
Harmonised Tripartite Guideline for Good Clinical Practice E6 (R1). The principles of the Declaration of 
Helsinki have all been implemented by means of the subject informed consent process, EC approval, 
study training, clinical study registration, preclinical testing, risk benefit assessment, and publication 
policy.  
Pediatric, legally incompetent, or other vulnerable subjects are not eligible for the study.  
The clinical investigation will not begin until all necessary approvals/favorable opinions are obtained 
from the appropriate IRB/ECs or regulatory authority, as appropriate. Should an IRB/EC or regulatory 
authority impose any additional requirements, they will be followed. 
Information regarding the study and study data will be made available via publication on clintrials.gov. 
Additionally, the results of this study will be submitted for publication in an appropriate journal. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 46 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
No insurance or compensation will be provided to study subjects. 
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB/EC. 
15. Study Administration 
15.1. Monitoring  
Site visits will be conducted by an authorized Medtronic representative to inspect study data, subjects’ 
medical records, and CRFs in accordance with current ICH GCPs and the respective local and national 
government regulations and guidelines (if applicable). The study investigator and the investigating site 
will permit authorized clinical research personnel and clinical monitors from Medtronic and/or 
designee(s) employed by Medtronic to review completed CRFs, IRB decisions, and Investigator, clinical 
site records, and facilities relevant to this study at regular intervals throughout the study per the 
monitoring plan. Additionally, subject charts and clinical records will be requested and reviewed so that 
protocol adherence and source documentation can be verified.  
The accuracy and quality of the data obtained from the investigator and maintained by the Sponsor will 
be confirmed through a structured program of clinical field auditing and internal review detailed in the 
monitoring plan. In instances where data protection regulations prohibit the direct examination of 
hospital records by the study Sponsor or designee(s), the Investigator will cooperate in a system of 
source data verification with the Sponsor. Monitoring may be performed with in person visits or 
remotely, when applicable.  
To ensure the rights, safety, and welfare of study subjects are being maintained, the monitor will 
maintain assurance that all study staff are trained on the CIP and use of the study devices. If the monitor 
discovers that an investigator is not complying with the signed Clinical Trial Agreement, the 
investigational plan, applicable laws, or any conditions of approval imposed by the reviewing IRB or 
Competent Authority, the monitor will report to the Sponsor and take such steps necessary to promptly 
secure compliance. If compliance cannot be secured, the investigator’s participation in the investigation 
may be terminated.  
Because there are no required medications for this study or other subject-generated reporting 
requirements, monitoring of subject compliance is not applicable to this study. 
For the purpose of this study, 100% of Endpoint Related data will be monitored. This is intended to 
include all data related to the calculation of the Primary or a Secondary Endpoint, as well as any data 
related to a Safety Event. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 47 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
15.2. Data Management 
This study will utilize an electronic database and eCRF. All data requested on the eCRF are considered 
required. Data points not collected and/or recorded will be considered deviations unless otherwise 
specified. No data points will be collected directly on the CRF. 
In order to accurately collect all information, subject worksheets may also be provided for study specific 
data (specific procedure data points, etc.) not found in the medical records and will be considered the 
source document.  
The Principal Investigator must ensure the accuracy and completeness of the recorded data and then 
provide his/her electronic signature on the appropriate CRFs. The Investigator’s signature for specific 
CRFs will be documented in compliance with local regulations. Changes to data previously submitted to 
the sponsor will require a new electronic signature by the Investigator to acknowledge/approve the 
changes. 
Visual and/or computer data review will be performed to identify possible data discrepancies. Manual 
and/or automatic discrepancies will be created in the Oracle remote data capture (RDC) system and will 
be issued to the site for appropriate response. The site staff will be responsible for resolving all 
discrepancies in the database. 
15.3. Direct Access to Source Data/Documents  
The investigator(s)/institution(s) will permit inspection and study-related monitoring, audits, IRB/IEC 
review, and regulatory inspection(s), including direct access to source data/documents.  
15.4. Confidentiality 
All records identifying the subject will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations, will not be made publicly available.  
Subject names will be kept confidential. Only the subject number will be recorded in the eCRF, and if the 
subject name appears on any other document, it must be obliterated.  
Study findings stored on a computer will be stored in accordance with local data protection laws. The 
subjects will be informed in writing that representatives of the sponsor, IRBs, or Regulatory Authorities 
may inspect their medical records to verify the information collected, and that all personal information 
made available for inspection will be handled in strictest confidence and in accordance with local data 
protection laws.  
Subjects will also be informed that information regarding the study that does not include subject 
identifiers will be posted on www.clinicaltrials.gov. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 48 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
If the results of the trial are published, the subject’s identity will remain confidential.  
The investigator will maintain a list to enable subjects’ records to be identified. 
15.5. Liability 
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB.  
15.6. CIP Amendments 
Should any amendment to the CIP be required, the CIP Author will collect and review all proposed 
updates. These will be incorporated as needed and approved per the CIP Approval Process. 
15.7. Record Retention 
The investigator will maintain the records of the study including all pertinent correspondence, the CIP 
with any/all amendments, all correspondence with and approval from the IRB, the clinical investigation 
agreement, the Clinical Trial Agreement, individual subject records, and signed ICFs. Subject files and 
other source data must be kept for a period of not less than two (2) years after the date on which this 
investigation is terminated or completed.  
Records may need to be maintained by the study investigator for a longer duration if national 
regulations require or if agreed to in writing with Medtronic. All data and documents should be made 
available if requested by relevant authorities.  
15.8. Publication and Use of Information 
The Medtronic Publication and Authorship Policy is aligned with the International Committee of Medical 
Journal Editors (ICMJE) recommendations (www.icmje.org). The Sponsor will seek to publish, in 
appropriate peer-reviewed journals and scientific conferences, results of clinical studies where human 
subjects are involved, regardless of outcome. While study results are owned by the Sponsor, all data on 
which a publication is based will be made available to all authors as required for their participation in 
the publication process. Furthermore, data may be published or used by study investigators provided 
that such publication or use is in accordance with this protocol, the Medtronic Publication and 
Authorship Policy, and the Clinical Investigation Agreement. Investigators must submit a copy of all 
manuscripts and/or abstracts to the Sponsor for review and comment 30 days prior to planned 
submission. Medtronic acknowledges that its right to review and comment shall relate solely to the 
proprietary, licensing, and/or confidential rights Medtronic may have in such proposed publication, 
rather than whether such results and/or opinions are favorable to Medtronic.  

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 49 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
The publication of substudies, post-hoc analyses, regional results, or single-center experiences based on 
multicenter clinical studies should not precede that of the primary multicenter publication, and should 
cite the primary publication whenever possible, as required by specific journal and scientific meeting 
guidelines.  
Medtronic involvement in a publication (e.g., funding of the study; sponsor of the study; collection, 
analysis, and interpretation of data; professional writing assistance) must be disclosed according to 
journal-specific policies, submission requirements, and prevailing editorial standards, in addition to 
those specified by International Committee of Medical Journal Editors. Authors must ensure that an 
acknowledgement/disclosure statement is included in the body of the manuscript for Medtronic to 
review for accuracy. All authors must also disclose financial or personal affiliations that could be 
considered conflicts of interest as per journal/conference requirements. 
To enable health care providers, payers, and patients access to the wealth of Medtronic’s research, 
Medtronic will report its scientific data in accordance with the principles outlined in the Guidance 
Document on Registration and Reporting Results of Company-Sponsored Clinical Trials, Section 801 of 
the Food and Drug Administration Amendments Act (FDAAA 801) and the Final Rule for Clinical Trials 
Registration and Results Information Submission (42 CFR Part 11, January 18, 2017). 
15.9. Suspension or Early Termination 
Medtronic reserves the right to discontinue the study at any stage, with suitable written notice to the 
investigator, the reviewing IRB, and applicable regulatory agencies. Similarly, the investigator may 
withdraw from the study at any time, subject to providing written notification to Medtronic 30 days 
prior to the date they intend to withdraw. However, Medtronic and the investigator will be bound by 
their obligation to complete the follow-up of subjects already participating in the study. The subjects 
must be followed according to the clinical protocol, and information obtained shall be reported to 
Medtronic on the appropriate CRF. 
Once the study is complete at the site, the investigator must submit a final report to their IRB and the 
sponsor per their IRB requirements. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 50 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
15.10. 
Study Contact Information 
Clinical Research 
Medical Affairs 
Scott Chouinard PhD 
Senior Director, Clinical Research 
Medtronic MITG 
Surgical Innovations 
15 Hampshire Street 
Mansfield, MA 02048 
 
 
Jennifer Mattingley MD 
Medical Affairs Director 
Lung Health, Surgical Innovations 
Minimally Invasive Therapies Group  
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
 
 
16. References 
 
1. 
National Cancer Institute, Cancer Therapy Evaluation Program, United States Department of 
Health and Human Services, National Institutes of Health. Common Terminology Criteria for 
Adverse Events (CTCAE) Version 5.0. Available at: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. 
Accessed January 23, 2018. 
2. 
Bowling MR, Anciano CJ. Updates in Advanced Diagnostic Bronchoscopy: Electromagnetic 
Navigational Bronchoscopy Chasing the Solitary Pulmonary Nodule. Clin Pulm Med. 
2017;24(2):60-5. doi: 10.1097/cpm.0000000000000191. PubMed PMID: 00045413-201703000-
00002. 
3. 
Becker HD, Herth F, Ernst A, Schwarz Y. Bronchoscopic biopsy of peripheral lung lesions under 
electromagnetic guidance: A pilot study. J Bronchology Interv Pulmonol. 2005;12(1):9-13. 
4. 
Gildea TR, Mazzone PJ, Karnak D, Meziane M, Mehta AC. Electromagnetic navigation diagnostic 
bronchoscopy: a prospective study. Am J Respir Crit Care Med. 2006;174(9):982-9. doi: 
10.1164/rccm.200603-344OC. PubMed PMID: 16873767; PubMed Central PMCID: PMC2648102. 
5. 
Schwarz Y, Greif J, Becker HD, Ernst A, Mehta A. Real-time electromagnetic navigation 
bronchoscopy to peripheral lung lesions using overlaid CT images: the first human study. Chest. 
2006;129(4):988-94. doi: 10.1378/chest.129.4.988. PubMed PMID: 16608948. 
6. 
Eberhardt R, Anantham D, Ernst A, Feller-Kopman D, Herth F. Multimodality bronchoscopic 
diagnosis of peripheral lung lesions: a randomized controlled trial. Am J Respir Crit Care Med. 
2007;176(1):36-41. doi: 10.1164/rccm.200612-1866OC. PubMed PMID: 17379850. 
7. 
Eberhardt R, Anantham D, Herth F, Feller-Kopman D, Ernst A. Electromagnetic navigation 
diagnostic bronchoscopy in peripheral lung lesions. Chest. 2007;131(6):1800-5. doi: 
10.1378/chest.06-3016. PubMed PMID: 17400670. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 51 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
8. 
Makris D, Scherpereel A, Leroy S, Bouchindhomme B, Faivre JB, Remy J, et al. Electromagnetic 
navigation diagnostic bronchoscopy for small peripheral lung lesions. Eur Respir J. 
2007;29(6):1187-92. doi: 10.1183/09031936.00165306. PubMed PMID: 17360724. 
9. 
Wilson DS, Bartlett RJ. Improved diagnostic yield of bronchoscopy in a community practice: 
Combination of electromagnetic navigation system and rapid on-site evaluation. J Bronchology 
Interv Pulmonol. 2007;14(4):227-32 doi: 10.1097/LBR.0b013e31815a7b00. 
10. 
Bertoletti L, Robert A, Cottier M, Chambonniere ML, Vergnon JM. Accuracy and feasibility of 
electromagnetic navigated bronchoscopy under nitrous oxide sedation for pulmonary peripheral 
opacities: an outpatient study. Respiration. 2009;78(3):293-300. doi: 10.1159/000226128. 
PubMed PMID: 19546519. 
11. 
Lamprecht B, Porsch P, Pirich C, Studnicka M. Electromagnetic navigation bronchoscopy in 
combination with PET-CT and rapid on-site cytopathologic examination for diagnosis of 
peripheral lung lesions. Lung. 2009;187(1):55-9. doi: 10.1007/s00408-008-9120-8. PubMed 
PMID: 18836886. 
12. 
Eberhardt R, Morgan RK, Ernst A, Beyer T, Herth FJ. Comparison of suction catheter versus 
forceps biopsy for sampling of solitary pulmonary nodules guided by electromagnetic 
navigational bronchoscopy. Respiration. 2010;79(1):54-60. doi: 10.1159/000232394. PubMed 
PMID: 19648733. 
13. 
Seijo LM, de Torres JP, Lozano MD, Bastarrika G, Alcaide AB, Lacunza MM, et al. Diagnostic yield 
of electromagnetic navigation bronchoscopy is highly dependent on the presence of a bronchus 
sign on CT imaging: results from a prospective study. Chest. 2010;138(6):1316-21. doi: 
10.1378/chest.09-2708. PubMed PMID: 20435658. 
14. 
Mahajan AK, Patel S, Hogarth DK, Wightman R. Electromagnetic navigational bronchoscopy: an 
effective and safe approach to diagnose peripheral lung lesions unreachable by conventional 
bronchoscopy in high-risk patients. J Bronchology Interv Pulmonol. 2011;18(2):133-7. doi: 
10.1097/LBR.0b013e318216cee6. PubMed PMID: 23169081. 
15. 
Brownback KR, Quijano F, Latham HE, Simpson SQ. Electromagnetic navigational bronchoscopy 
in the diagnosis of lung lesions. J Bronchology Interv Pulmonol. 2012;19(2):91-7. doi: 
10.1097/LBR.0b013e31824dd9a1. PubMed PMID: 23207349. 
16. 
Jensen KW, Hsia DW, Seijo LM, Feller-Kopman DJ, Lamb C, Berkowitz D, et al. Multicenter 
experience with electromagnetic navigation bronchoscopy for the diagnosis of pulmonary 
nodules. J Bronchology Interv Pulmonol. 2012;19(3):195-9. doi: 
10.1097/LBR.0b013e3182616ece. PubMed PMID: 23207460. 
17. 
Lamprecht B, Porsch P, Wegleitner B, Strasser G, Kaiser B, Studnicka M. Electromagnetic 
navigation bronchoscopy (ENB): Increasing diagnostic yield. Respir Med. 2012;106(5):710-5. doi: 
10.1016/j.rmed.2012.02.002. PubMed PMID: 22391437. 
18. 
Pearlstein DP, Quinn CC, Burtis CC, Ahn KW, Katch AJ. Electromagnetic navigation bronchoscopy 
performed by thoracic surgeons: one center's early success. Ann Thorac Surg. 2012;93(3):944-9; 
discussion 9-50. doi: 10.1016/j.athoracsur.2011.11.006. PubMed PMID: 22277964. 
19. 
Balbo PE, Bodini BD, Patrucco F, Della Corte F, Zanaboni S, Bagnati P, et al. Electromagnetic 
navigation bronchoscopy and rapid on site evaluation added to fluoroscopy-guided assisted 
bronchoscopy and rapid on site evaluation: improved yield in pulmonary nodules. Minerva Chir. 
2013;68(6):579-85. PubMed PMID: 24193290. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 52 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
20. 
Karnak D, Ciledag A, Ceyhan K, Atasoy C, Akyar S, Kayacan O. Rapid on-site evaluation and low 
registration error enhance the success of electromagnetic navigation bronchoscopy. Ann Thorac 
Med. 2013;8(1):28-32. doi: 10.4103/1817-1737.105716. PubMed PMID: 23440066; PubMed 
Central PMCID: PMC3573554. 
21. 
Khan AY, Berkowitz D, Krimsky WS, Hogarth DK, Parks C, Bechara R. Safety of pacemakers and 
defibrillators in electromagnetic navigation bronchoscopy. Chest. 2013;143(1):75-81. doi: 
10.1378/chest.12-0689. PubMed PMID: 22922452. 
22. 
Mohanasundaram U, Ho LA, Kuschner WG, Chitkara RK, Canfield J, Canfield LM, et al. The 
Diagnostic Yield of Navigational Bronchoscopy Performed with Propofol Deep Sedation. ISRN 
Endoscopy. 2013;2013:1-5. doi: 10.5402/2013/824693. 
23. 
Loo FL, Halligan AM, Port JL, Hoda RS. The emerging technique of electromagnetic navigation 
bronchoscopy-guided fine-needle aspiration of peripheral lung lesions: promising results in 50 
lesions. Cancer Cytopathol. 2014;122(3):191-9. doi: 10.1002/cncy.21373. PubMed PMID: 
24323803. 
24. 
Odronic SI, Gildea TR, Chute DJ. Electromagnetic navigation bronchoscopy-guided fine needle 
aspiration for the diagnosis of lung lesions. Diagn Cytopathol. 2014;42(12):1045-50. doi: 
10.1002/dc.23164. PubMed PMID: 24692403. 
25. 
Bowling MR, Kohan MW, Walker P, Efird J, Ben Or S. The effect of general anesthesia versus 
intravenous sedation on diagnostic yield and success in electromagnetic navigation 
bronchoscopy. J Bronchology Interv Pulmonol. 2015;22(1):5-13. doi: 
10.1097/LBR.0000000000000120. PubMed PMID: 25590477. 
26. 
Al-Jaghbeer M, Marcus M, Durkin M, McGuire FR, Iftikhar IH. Diagnostic yield of electromagnetic 
navigational bronchoscopy. Ther Adv Respir Dis. 2016;10(4):295-9. doi: 
10.1177/1753465816637053. PubMed PMID: 26944363. 
27. 
Garwood SK, ClenDening P, Hevelone ND, Hood KL, Pidgeon S, Wudel LJ. Navigational 
bronchoscopy at a community hospital: clinical and economic outcomes. Lung Cancer 
Management. 2016;5(3):131-40. doi: 10.2217/lmt-2016-0015. 
28. 
Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-Mendoza J, et al. Diagnostic yield and 
complications of bronchoscopy for peripheral lung lesions. Results of the AQuIRE Registry. Am J 
Respir Crit Care Med. 2016;193(1):68-77. doi: 10.1164/rccm.201507-1332OC. PubMed PMID: 
26367186. 
29. 
Ozgul G, Cetinkaya E, Ozgul MA, Abul Y, Gencoglu A, Kamiloglu E, et al. Efficacy and safety of 
electromagnetic navigation bronchoscopy with or without radial endobronchial ultrasound for 
peripheral lung lesions. Endosc Ultrasound. 2016;5(3):189-95. doi: 10.4103/2303-9027.183979. 
PubMed PMID: 27386477. 
30. 
Bowling MR, Brown C, Anciano CJ. Feasibility and Safety of the Transbronchial Access Tool for 
Peripheral Pulmonary Nodule and Mass. Ann Thorac Surg. 2017;104:443-9. doi: 
10.1016/j.athoracsur.2017.02.035. PubMed PMID: 28527967. 
31. 
Copeland S, Kambali S, Berdine G, Alalawi R. Electromagnetic navigational bronchoscopy in 
patients with solitary pulmonary nodules. The Southwest Respiratory and Critical Care 
Chronicles. 2017;5(17):12-6. Epub 2017-01-15. doi: 10.12746/swrccc2017.0517.235. 
32. 
Mukherjee S, Chacey M. Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Using a 
Curved-tip Catheter to Aid in the Diagnosis of Pulmonary Lesions. J Bronchology Interv 
Pulmonol. 2017;24(1):35-9. doi: 10.1097/LBR.0000000000000326. PubMed PMID: 27623421. 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 53 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
33. 
Saenghirunvattana S, Bechara R, Saenghirunvattana C, Gonzales MC, Sutthisri K, Siangpro C. 
Electromagnetic Navigation Bronchoscopy. BKK Med J. 2017;13(1):37-40. 
34. 
Sun J, Xie F, Zheng X, Jiang Y, Zhu L, Mao X, et al. Learning curve of electromagnetic navigation 
bronchoscopy for diagnosing peripheral pulmonary nodules in a single institution. Translational 
Cancer Research. 2017. 
35. 
Gex G, Pralong JA, Combescure C, Seijo L, Rochat T, Soccal PM. Diagnostic yield and safety of 
electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-
analysis. Respiration. 2014;87(2):165-76. doi: 10.1159/000355710. PubMed PMID: 24401166. 
36. 
DiBardino DM, Yarmus LB, Semaan RW. Transthoracic needle biopsy of the lung. J Thorac Dis. 
2015;7(Suppl 4):S304-16. doi: 10.3978/j.issn.2072-1439.2015.12.16. PubMed PMID: 26807279; 
PubMed Central PMCID: PMC4700361. 
37. 
Khandhar SJ, Bowling MR, Flandes J, Gildea TR, Hood KL, Krimsky WS, et al. Electromagnetic 
navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, 
multicenter NAVIGATE study. BMC Pulm Med. 2017;17(1):59. doi: 10.1186/s12890-017-0403-9. 
38. 
Herth FJ, Eberhardt R, Becker HD, Ernst A. Endobronchial ultrasound-guided transbronchial lung 
biopsy in fluoroscopically invisible solitary pulmonary nodules: a prospective trial. Chest. 
2006;129(1):147-50. doi: 10.1378/chest.129.1.147. PubMed PMID: 16424425. 
39. 
Folch EE, Bowling MR, Gildea TR, Hood KL, Murgu SD, Toloza EM, et al. Design of a prospective, 
multicenter, global, cohort study of electromagnetic navigation bronchoscopy. BMC Pulm Med. 
2016;16(1):60. doi: 10.1186/s12890-016-0228-y. PubMed PMID: 27113209. 
40. 
Steinfort DP, Einsiedel P, Irving LB. Radiation dose to patients and clinicians during 
fluoroscopically-guided biopsy of peripheral pulmonary lesions. Respir Care. 2010;55(11):1469-
74. Epub 2010/10/29. PubMed PMID: 20979674. 
41. 
Hohenforst-Schmidt W, Banckwitz R, Zarogoulidis P, Vogl T, Darwiche K, Goldberg E, et al. 
Radiation exposure of patients by cone beam CT during endobronchial navigation-a phantom 
study. J Cancer. 2014;5(3):192. 
 
  
 
 
 
 
 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
 
 
MDT18004ILSFNV 
Version 1.0 
Page 54 of 54 
 
This document is electronically controlled  
 
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
18. Version History 
Version 
Summary of Changes 
Author(s)/Title 
1.0 
• 
Not applicable (new document) 
Sean Pidgeon, Senior Clinical Research 
Specialist 
Kristin Hood, Senior Principal Medical 
Writer